India’s central government restricts certain combination cold medicines for children under four, citing safety concerns. The fixed-dose combination of chlorpheniramine maleate and phenylephrine hydrochloride is now banned for this age group, according to reports. NDTV also identifies this two-ingredient combination as being used for common-cold symptom relief.
Times of India reports that the regulatory move follows reviews by expert committees and recommendations that question the risk profile of such fixed-dose combinations in very young children. The outlet says manufacturers are required to prominently display warnings on labels for affected medicines, reflecting the government’s intent to alert caregivers and health providers. While the outlets differ in emphasis—NDTV focusing on the ingredient pairing and its use, and Times of India detailing the restrictions, rationale, and labeling requirements—they both point to the same core action: curbs on the chlorpheniramine–phenylephrine combination for children under four.
Overall, the reporting aligns on the identification of the specific combination and the direction of the policy change, with additional details on implementation and process highlighted by one outlet.
